Rome-based Angelini Pharma has inked a multi-year deal with Massachusetts biotech Quiver Bioscience that is designed to advance novel therapies for genetic epilepsies and could garner up to $120 million in milestone payments for the latter.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Rome-based Angelini Pharma has inked a multi-year deal with Massachusetts biotech Quiver Bioscience that is designed to advance novel therapies for genetic epilepsies and could garner up to $120 million in milestone payments for the latter.